Tvardi Therapeutics Q2 net loss slightly lower estimates
TVRD•Development costs and outlook
The company said second-quarter results also reflected increased development costs for its next-generation STAT3 inhibitor TTI-109, partially offsetting lower clinical costs for TTI-101.
Tvardi expects existing cash to fund operations through the HCC topline readout into Q3 2027. The company plans to initiate a TTI-109 ulcerative colitis clinical trial in 2027, subject to IND clearance and funding. Advancing TTI-109 into UC and other indications will require additional funding and IND clearance.
Analyst coverage and valuation
The current average analyst rating on the shares is "buy", with 7 "strong buy" or "buy", 1 "hold", and 1 "sell" or "strong sell" recommendation.
The average consensus recommendation for the biotechnology & medical research peer group is "buy". Wall Street's median 12-month price target for Tvardi Therapeutics, Inc. is $9.50, about 436.7% above its August 13 closing price of $1.77.
